meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
3
mHCC - 1st line (L1)
10
mHCC - 2nd line (L2)
2
lung cancer : non small cell (NSCLC)
5
antibody–drug conjugate
trastuzumab deruxtecan
chemotherapy
antifolates
pralatrexate
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus BSC
gene alteration target therapy
ALK inhibitors
alectinib
brigatinib
ceritinib
crizotinib
BRAF gene alteration targeted therapy
BRAF inhibitor
combined BRAF-MEK inhibitors
trametinib plus dabrafenib
EGFR gene alteration
amivantamab-vmjw
mobocertinib
osimertinib
KRAS gene alteration targeted therapy
adagrasib
sotorasib
MET gene alteration targeted therapy
capmatinib
savolitinib
tepotinib
NTRK gene alteration targeted therapy
entrectinib
larotrectinib
RET gene alteration targeted therapy
pralsetinib
selpercatinib
ROS1 and TRK TKI
repotrectinib
HER inhibitor
EGFR inhibitor
afatinib based treatment
afatinib alone
afatinib plus BSC
afatinib plus paclitaxel
dacomitinib
erlotinib based treatment
erlotinib alone
erlotinib followed by gemcitabine plus platin
erlotinib plus bevacizumab
erlotinib plus cisplatin and gemcitabine
erlotinib plus gemcitabine
erlotinib plus pemetrexed
erlotinib plus SoC
tivantinib plus erlotinib
gefitinib based treatment
gefitinib alone
gefitinib plus BSC
gefitinib plus pemetrexed plus platin
gefitinib plus SoC
gefitinib plus SoC (rechallenge)
pemetrexed plus platin followed by maintenance gefitinib
SoC followed by gefitinib
icotinib
naquotinib
nimotuzumab based treatment
nimotuzumab plus gefitinib
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
ipilimumab plus SoC
ipilimumab followed by nivolumab
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus paclitaxel
atezolizumab plus pemetrexed and platin
avelumab based treatment
avelumab alone
cemiplimab
durvalumab based treatment
durvalumab alone
durvalumab plus osimertinib
durvalumab plus SoC
nivolumab based treatment
nivolumab alone
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (2mg/kg)
pembrolizumab and pemetrexed plus platin
pembrolizumab followed by nab-paclitaxel
pembrolizumab plus SoC
sintilimab based treatment
sintillimab plus SoC
sugemalimab based treatment
Sugemalimab
sugemalimab plus SoC
Tislelizumab
anti-TIGIT
tiragolumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
pembrolizumab plus ipilimumab
VEGF(R) inhibitor
ramucirumab
ramucirumab plus erlotinib
sorafenib
sorafenib and erlotinib
vandetanib
no study with result for this clinical condition